Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 Meeting Abstract
| Authors: | Reck, M.; Ciuleanu, T. E.; Pluzanski, A.; Lee, J. S.; Bernabe Caro, R.; Linardou, H.; Burgers, J.; Gallardo, C.; Nishio, M.; Peters, S.; Paz-Ares, L. G.; Hellmann, M. D.; Borghaei, H.; Ramalingam, S. S.; O'Byrne, K.; Hu, N.; Bushong, J.; Eccles, L.; Grootendorst, D.; Brahmer, J. R. |
| Abstract Title: | Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 |
| Meeting Title: | ESMO Immuno-Oncology Congress 2021 |
| Journal Title: | Annals of Oncology |
| Volume: | 32 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2021 Dec 8-11 |
| Meeting Location: | Virtual |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2021-12-01 |
| Start Page: | S1430 |
| End Page: | S1431 |
| Language: | English |
| ACCESSION: | WOS:000731051400125 |
| DOI: | 10.1016/j.annonc.2021.10.141 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 122MO -- Source: Wos |
